Project Grant R01CA314250
Award Date 7/16/26
Completion Date 6/30/31
Dollars Obligated $626K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Austin, TX 78712, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded a $396,377 Project Grant to the University of Texas at Austin under the Cancer Cause and Prevention Research program (CFDA 93.393) to characterize mutational signatures at hotspots of genetic instability in human cancer genomes. The research integrates large-scale cancer genome analyses, gene perturbation experiments, and environmental mutagen exposure data to uncover the mutational processes driving genomic instability at non-B...
- Federal Grant Award Summary Award Details: Funding Agency: National Cancer Institute Federal Grant Program: Cancer Cause and Prevention Research (CFDA 93.393) Award Amount: $460,254 Award Date: July 16, 2026 Completion Date: June 30, 2028 Awardee: HMH Hospitals Corporation (Hackensack University Medical Center), Edison, NJ Research Products and Services: This Project Grant supports basic and translational research aimed at identifying predictive and prognostic adipome biomarkers in obese...
- Federal Grant Award Summary The National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), awarded a $401,115 Project Grant to the University of Texas Health Science Center at Houston for a two-year research initiative spanning August 1, 2026, through July 31, 2028. The award supports fundamental research investigating the molecular mechanisms by which hepatic Sirtuin 3 (SIRT3) regulates the progression from metabolic dysfunction-associated steatohepatitis (MASH)...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $490,836 Project Grant to the Regents of the University of Michigan on June 19, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393). The five-year award, which runs through May 31, 2031, funds research examining the clinical transition from active surveillance to observation management in older men (age 65+) with low-risk prostate cancer. The study addresses a significant gap in understanding how and...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $588,677 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of Arizona, with an award date of July 1, 2026, and a project completion date of June 30, 2031. The research focuses on identifying the mechanisms by which oxygen-dependent centrosome instability drives prostate cancer progression. Specifically, the project investigates how hypoxia induces centrosome loss and...
- Federal Project Grant Award Summary The University of Pennsylvania received a $467,406 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) effective July 1, 2026, through June 30, 2031. This award funds research investigating the role of Nicotinamide N-Methyltransferase (NNMT) in prostate cancer etiology and progression. The research will examine how tumor-specific loss of NNMT leads to excess S-Adenosylmethionine (SAM)...
- Federal Grant Award Summary The National Cancer Institute awarded a $680,600 Project Grant to The University of Texas MD Anderson Cancer Center on September 19, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and evaluate a family-centered lifestyle intervention for Black prostate cancer survivors and their caregivers. The grant supports a randomized controlled trial examining the efficacy of a dyadic-focused intervention designed to improve physical...
- Federal Grant Award Summary The University of Texas Health Science Center at San Antonio received a $482,637 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), effective June 16, 2026, with a completion date of May 31, 2031. The grant supports research into the molecular mechanisms of ring-between-ring (RBR) ubiquitin signaling in DNA repair, specifically investigating the ARIH1 protein's role in facilitating...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $688,073 Project Grant on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to The University of Texas MD Anderson Cancer Center for a five-year project extending through May 31, 2031. This award funds the development of novel computational and molecular archaeology approaches to reconstruct and elucidate the evolutionary history of cancer metastases. The research addresses a critical knowledge gap...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $370,173 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded September 9, 2025, with a completion date of August 31, 2030. This project delivers research and development of advanced genetic interaction measurement and characterization methodologies for cancer cells, with a primary focus on synthetic lethality as a...